Skip to main
CLDX

Celldex Therapeutics (CLDX) Stock Forecast & Price Target

Celldex Therapeutics (CLDX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Celldex Therapeutics is positioned for success due to the potential efficacy deterioration of its competitor drugs, its best-in-disease overall urticaria control and potential for angioedema benefit, and its leadership position in the mast cell space, as evidenced by its strong Phase II data, accelerated enrollment, and broad pipeline opportunities in multiple indications. Additionally, the company's current pipeline holds a high potential for success, including its flagship drug barzolvolimab which has shown promise in treating both chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The company's Phase III EMBARQ-CSU trials have completed enrollment ahead of schedule, demonstrating significant unmet need for effective treatments in this space.

Bears say

Celldex Therapeutics is facing significant regulatory risks in the development of its potential mast cell-targeting drug portfolio, as evidenced by the recent failure of its barzolvolimab in a Phase 2 trial for prurigo nodularis (PN). Despite promising proof-of-concept data, Celldex's potential mast cell-targeting approach may not be effective in treating certain inflammatory diseases, potentially hindering the company's future revenue prospects. Furthermore, the company's high valuation based on a probability-adjusted DCF analysis suggests that investors may be overestimating the long-term potential of its pipeline, warranting caution in investing in Celldex's stock.

Celldex Therapeutics (CLDX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celldex Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celldex Therapeutics (CLDX) Forecast

Analysts have given Celldex Therapeutics (CLDX) a Buy based on their latest research and market trends.

According to 11 analysts, Celldex Therapeutics (CLDX) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celldex Therapeutics (CLDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.